Email to a Colleague
Medscape Conference Coverage, based on selected sessions at the:
American Society of Hypertension 20th Annual Scientific Meeting and Exposition
May 14 - 18, 2005, San Francisco, California

This activity is not sanctioned by, nor a part of, the American Society of Hypertension.


Also On This Page:Session CoverageConference News
Topic Overviews
Highlights From the American Society of Hypertension 20th Annual Scientific Meeting and Exposition CME
Physicians - up to 0.5 hour(s) of AMA PRA category 1 credit
The "New Definition" of Hypertension Must Include Overall Risk
Norman D. Kaplan, MD
Managing Hypertension: Assessing Parameters To Enhance Clinical Practice
Domenic Sica, MD
Expert Interview
The Evolving Definition and Classification of Hypertension: An Expert Interview With John B. Kostis, MD
What should be the definition of hypertension -- or does it even exist? Surprisingly, these questions are being debated, as discussed here by a leading authority.
Blood Pressure Control and Prevention of Chronic Kidney Disease: An Expert Interview With George L. Bakris, MD
It is no longer a question of whether it's hypertension or renal disease -- it's how to recognize and treat which patients and when, as addressed here by a leading expert.
Session Coverage
New Definition of Hypertension Proposed
Is it time to update the definition of hypertension -- or does hypertension even exist? Such were the questions asked by the American Society of Hypertension this year.
AVALON-AWC: Arterial Wall Compliance in the Atorvastatin and Amlodipine in Patients With Elevated Lipids and Hypertension Trial
Arterial wall stiffness is one of the first signs of cardiovascular disease, and this new methodology appears to provide a reliable assessment of this parameter.
New-Onset Diabetes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial
Post-hoc analysis of the VALUE results document a lower rate of new-onset diabetes during follow-up for patients on the ARB.
INCLUSIVE: Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations
The use of fixed-dose combination agents is becoming more and more popular, but which drugs, in which combination, in which all "inclusive" populations?
International Verapamil SR-Trandolapril Study (INVEST) -- Subanalysis of Black Patients
Treatment usage rates were different, achieved blood pressures were different, but there were no significant differences in outcomes between races in this prespecified subanalysis of INVEST.
Renin Inhibitor Shows Parallel Reductions in SBP and PRA
Blockade of the RAS through ACE inhibition has well-known, well-proven benefit -- but shouldn't the more elegant step of specific blockade of renin itself be at least as effective?
Conference News
Mental Stress-Associated Blood Pressure Rise Linked to Increase in Creatinine 5/20/05
[Medscape Medical News]
Patients who have blood pressure that is highly reactive to mental stress are more likely to have hypertension and elevated creatinine levels.
Fixed-Dose Drug Regimen Better Than Add-on Drug for Systolic Hypertension 5/18/05
[Medscape Medical News]
The group receiving the fixed dose had fewer adverse events compared with the drug add-on group, according to researchers.
High Plasma Renin Activity Predicts Myocardial Infarction Even in Treated Hypertension 5/17/05
[Medscape Medical News]
Men with left ventricular hypertrophy had twice the risk of myocardial infarction and revascularization procedures, according to the study results.

 
Legal Disclaimer
The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American Society of Hypertension. These materials and the related activity are not sanctioned by the American Society of Hypertension or the commercial supporter of the conference, and do not constitute an official part of that conference.
The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.
Copyright © 2005 Medscape.

 


Pfizer, Novartis

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.